Open Access
Subscription Access
Drugs Acting on Hyperlipidemia
Abstract
Statins are utilized for hyperlipidemia because of their effectiveness in decreasing LDL cholesterol, thar is bad cholesterol. These drugs stop HMG _ CoA reductase, a key enzyme in cholesterol synthesis. Statins can cause enhancement in the number of LDL receptors on the liver cells, favoring the removal of LDL from the blood stream. Ezetimibe acts by a different mechanism. Protein convertase subtilisin/ kex in type a ( PCSK 9 ) inhibitors Areca relatively newer class of drugs. By stopping PCSK 9, these drugs enhance the number of LDL receptors, increasing the removal of cholesterol from the blood stream. Fibrate influence Triglyceride levels. They stimulate peroxisomems proliferation _ activated receptors ( PPARs), resulting in enhanced breakdown of triglycerides and a rise in HDL cholesterol. Niacin termed ad vitamin B 3 enhance HDL cholesterol and decrease LDL as well as Triglyceride levels. Omega_ 3 fatty acids decrease the Triglycerides in the liver. Finally it us concluded that the management of hyperlipidemua involves a nuanced approach and considers the specific lipid profile of each individual.
References
Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med. 1971 Sep;75(3):471-2. [PubMed]
Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH, Haffner SM. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab. 2000 Jun;85(6):2089-112. [PubMed]
Faxon DP, Fuster V, Libby P, Beckman JA, Hiatt WR, Thompson RW, Topper JN, Annex BH, Rundback JH, Fabunmi RP, Robertson RM, Loscalzo J., American Heart Association. Atherosclerotic Vascular Disease Conference: Writing Group III: pathophysiology. Circulation. 2004 Jun 01;109(21):2617-25. [PubMed]
Vodnala D, Rubenfire M, Brook RD. Secondary causes of dyslipidemia. Am J Cardiol. 2012 Sep 15;110(6):823-5. [PubMed]
Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986 Nov 28;256(20):2823-8. [PubMed]
The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984 Jan 20;251(3):365-74. [PubMed]
Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT., ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J. 2016 Oct 14;37(39):2999-3058. [PubMed]
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA., GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016 Apr 19;315(15):1580-90. [PubMed]
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up. Circulation. 2017 Nov 14;136(20):1878-1891. [PubMed]
Ford I, Murray H, McCowan C, Packard CJ. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Circulation. 2016 Mar 15;133(11):1073-80. [PMC free article] [PubMed]
Refbacks
- There are currently no refbacks.